|By Marketwired .||
|November 27, 2012 01:44 AM EST||
MARTINSRIED, GERMANY and MUNICH, GERMANY -- (Marketwire) -- 11/27/12 -- MorphoSys AG / MorphoSys and Lanthio Pharma Sign Technology Alliance on New Class of Therapeutic Peptides. Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.
MorphoSys to Participate in Lanthio Pharma's Series A Financing
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) today announced a collaboration with privately held Lanthio Pharma, a Dutch biopharmaceutical company focused on discovering and developing lantipeptides. Lantipeptides comprise a novel class of therapeutics with high target selectivity and improved drug-like properties. Lanthio Pharma's technology LanthioPep can be used to identify peptides which are selective for a specific disease target and to stabilize them in their optimal structural conformation for receptor binding. MorphoSys and Lanthio Pharma will jointly apply their respective technologies to establish high quality and diverse lantipeptide-based libraries. MorphoSys receives preferred rights to exclusively license the LanthioPep technology for drug discovery.
MorphoSys will also make an equity investment in Lanthio Pharma as part of the company's Series A financing round. After closure of the transaction, MorphoSys will have a minority stake in Lanthio Pharma.
"Therapeutic peptides and especially so called stapled or constrained peptides comprise an emerging compound class which offers the potential to address multiple target classes and disease categories currently beyond reach for therapeutic proteins or small molecules. The combination of Lanthio Pharma's platform and our expertise in intelligent library design offers unique opportunities for both companies and that's what got us excited," commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG.
"We are very pleased to have access to this novel technology platform and promising class of therapeutic peptides," commented Jens Holstein, Chief Financial Officer of MorphoSys. "This transaction represents a new approach for MorphoSys providing innovation capital to promising start-ups with technologies and product candidates being close to our core capabilities."
Lanthio Pharma applies its proprietary LanthioPep technology to discover peptide therapeutics with increased resistance to peptidase degradation, high receptor specificity and increased intrinsic activity. The high specificity can open up new therapeutic applications around novel targets including intracellular targets and GPCRs. Therapeutic plasma levels of lantipeptides can potentially be achieved via oral, pulmonary or subcutaneous delivery. The technology includes a proprietary bacterial display capability, which allows for the construction of focused or diversified libraries of lanthionine-peptides. These libraries allow for immediate functional screening and easy production of peptides of interest for further in vivo and in vitro testing. Lanthio Pharma signed a partnering deal for its lead compound PanCyte, a lanthionine-stabilized Angiotensin-(1-7) agonistic peptide for the treatment of pulmonary indications, with US-based Tarix Pharmaceuticals, Inc. in 2012. The start of clinical development of PanCyte is expected in 2013.
"Peptides are an attractive class of drugs, because they are used by the body itself to regulate physiological processes. A drawback of using peptides therapeutically can be their ability to interact with several receptors and their rapid degradation by peptidases in the body. Lanthio Pharma's technology can make peptides more receptor specific and the introduction of lanthionines also provides strong protection against peptidase degradation. As such, our lantipeptides typically have better "drug-like" properties, compared to natural linear peptides. In combination with MorphoSys's outstanding capabilities in generating high-quality protein libraries we are confident that we can bring lantipeptides to the next level," commented Bart Wuurman, CEO of Lanthio Pharma.
About Lanthio Pharma:
Lanthio Pharma is a privately held drug discovery company that applies its proprietary Lactococcus lactis based lanthionine-peptide drug discovery (LanthioPep) technology to discover peptide therapeutics with increased resistance to peptidase degradation, high receptor specificity and increased intrinsic activity. Lanthio Pharma has generated stable, peptidase-resistant lanthionine peptides with highly specific agonistic activity for a number of GPCR targets, which is a focus area of the company. Many peptide ligands are thought to bind to their GPCR receptors via a "turn motif", which can be stabilized in Lanthio Pharma's peptides with a strong thioether bond. Fixing the turn motif in its optimal receptor binding conformation can result in potent and specific agonistic receptor activation. The technology also includes a proprietary bacterial display library capability, which allows for the construction of focused or randomized libraries. These libraries allow for immediate functional screening and easy production of peptides of interest for further in-vivo and in-vitro testing. Therapeutic products in Lanthio Pharma's pipeline include a lanthionine-stabilized specific agonist of the AT2 receptor, which has great potential in diseases where tissue protection is important, like fibrosis.
MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare. The company's AbD Serotec unit uses HuCAL and other antibody technologies to generate superior monoclonal antibodies for research and diagnostic applications. Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 70 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla® and Ylanthia® and 100 billion high potentials® are registered trademarks of MorphoSys AG.
Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a subsidiary of MorphoSys AG.
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.
Media Release (PDF): http://hugin.info/130295/R/1660628/537803.pdf
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE
For more information, please contact:
Dr. Claudia Gutjahr-Loser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332
A strange thing is happening along the way to the Internet of Things, namely far too many devices to work with and manage. It has become clear that we'll need much higher efficiency user experiences that can allow us to more easily and scalably work with the thousands of devices that will soon be in each of our lives. Enter the conversational interface revolution, combining bots we can literally talk with, gesture to, and even direct with our thoughts, with embedded artificial intelligence, wh...
Sep. 27, 2016 05:00 AM EDT Reads: 3,539
Digital transformation is too big and important for our future success to not understand the rules that apply to it. The first three rules for winning in this age of hyper-digital transformation are: Advantages in speed, analytics and operational tempos must be captured by implementing an optimized information logistics system (OILS) Real-time operational tempos (IT, people and business processes) must be achieved Businesses that can "analyze data and act and with speed" will dominate those t...
Sep. 27, 2016 04:45 AM EDT Reads: 1,128
The Jevons Paradox suggests that when technological advances increase efficiency of a resource, it results in an overall increase in consumption. Writing on the increased use of coal as a result of technological improvements, 19th-century economist William Stanley Jevons found that these improvements led to the development of new ways to utilize coal. In his session at 19th Cloud Expo, Mark Thiele, Chief Strategy Officer for Apcera, will compare the Jevons Paradox to modern-day enterprise IT, e...
Sep. 27, 2016 04:30 AM EDT Reads: 1,915
There are several IoTs: the Industrial Internet, Consumer Wearables, Wearables and Healthcare, Supply Chains, and the movement toward Smart Grids, Cities, Regions, and Nations. There are competing communications standards every step of the way, a bewildering array of sensors and devices, and an entire world of competing data analytics platforms. To some this appears to be chaos. In this power panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, Bradley Holt, Developer Advocate a...
Sep. 27, 2016 04:15 AM EDT Reads: 2,034
More and more companies are looking to microservices as an architectural pattern for breaking apart applications into more manageable pieces so that agile teams can deliver new features quicker and more effectively. What this pattern has done more than anything to date is spark organizational transformations, setting the foundation for future application development. In practice, however, there are a number of considerations to make that go beyond simply “build, ship, and run,” which changes ho...
Sep. 27, 2016 04:00 AM EDT Reads: 2,377
SYS-CON Events announced today the Kubernetes and Google Container Engine Workshop, being held November 3, 2016, in conjunction with @DevOpsSummit at 19th Cloud Expo at the Santa Clara Convention Center in Santa Clara, CA. This workshop led by Sebastian Scheele introduces participants to Kubernetes and Google Container Engine (GKE). Through a combination of instructor-led presentations, demonstrations, and hands-on labs, students learn the key concepts and practices for deploying and maintainin...
Sep. 27, 2016 04:00 AM EDT Reads: 2,682
In his general session at 18th Cloud Expo, Lee Atchison, Principal Cloud Architect and Advocate at New Relic, discussed cloud as a ‘better data center’ and how it adds new capacity (faster) and improves application availability (redundancy). The cloud is a ‘Dynamic Tool for Dynamic Apps’ and resource allocation is an integral part of your application architecture, so use only the resources you need and allocate /de-allocate resources on the fly.
Sep. 27, 2016 03:45 AM EDT Reads: 2,564
Without a clear strategy for cost control and an architecture designed with cloud services in mind, costs and operational performance can quickly get out of control. To avoid multiple architectural redesigns requires extensive thought and planning. Boundary (now part of BMC) launched a new public-facing multi-tenant high resolution monitoring service on Amazon AWS two years ago, facing challenges and learning best practices in the early days of the new service. In his session at 19th Cloud Exp...
Sep. 27, 2016 03:15 AM EDT Reads: 988
There is growing need for data-driven applications and the need for digital platforms to build these apps. In his session at 19th Cloud Expo, Muddu Sudhakar, VP and GM of Security & IoT at Splunk, will cover different PaaS solutions and Big Data platforms that are available to build applications. In addition, AI and machine learning are creating new requirements that developers need in the building of next-gen apps. The next-generation digital platforms have some of the past platform needs a...
Sep. 27, 2016 03:00 AM EDT Reads: 1,799
SYS-CON Events announced today that Bsquare has been named “Silver Sponsor” of SYS-CON's @ThingsExpo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. For more than two decades, Bsquare has helped its customers extract business value from a broad array of physical assets by making them intelligent, connecting them, and using the data they generate to optimize business processes.
Sep. 27, 2016 03:00 AM EDT Reads: 2,756
SYS-CON Events announced today that ReadyTalk, a leading provider of online conferencing and webinar services, has been named Vendor Presentation Sponsor at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. ReadyTalk delivers audio and web conferencing services that inspire collaboration and enable the Future of Work for today’s increasingly digital and mobile workforce. By combining intuitive, innovative tec...
Sep. 27, 2016 03:00 AM EDT Reads: 2,934
Fact is, enterprises have significant legacy voice infrastructure that’s costly to replace with pure IP solutions. How can we bring this analog infrastructure into our shiny new cloud applications? There are proven methods to bind both legacy voice applications and traditional PSTN audio into cloud-based applications and services at a carrier scale. Some of the most successful implementations leverage WebRTC, WebSockets, SIP and other open source technologies. In his session at @ThingsExpo, Da...
Sep. 27, 2016 02:15 AM EDT Reads: 1,600
While DevOps promises a better and tighter integration among an organization’s development and operation teams and transforms an application life cycle into a continual deployment, Chef and Azure together provides a speedy, cost-effective and highly scalable vehicle for realizing the business values of this transformation. In his session at @DevOpsSummit at 19th Cloud Expo, Yung Chou, a Technology Evangelist at Microsoft, will present a unique opportunity to witness how Chef and Azure work tog...
Sep. 27, 2016 02:15 AM EDT Reads: 1,721
Cognitive Computing is becoming the foundation for a new generation of solutions that have the potential to transform business. Unlike traditional approaches to building solutions, a cognitive computing approach allows the data to help determine the way applications are designed. This contrasts with conventional software development that begins with defining logic based on the current way a business operates. In her session at 18th Cloud Expo, Judith S. Hurwitz, President and CEO of Hurwitz & ...
Sep. 27, 2016 02:15 AM EDT Reads: 3,040
Almost two-thirds of companies either have or soon will have IoT as the backbone of their business in 2016. However, IoT is far more complex than most firms expected. How can you not get trapped in the pitfalls? In his session at @ThingsExpo, Tony Shan, a renowned visionary and thought leader, will introduce a holistic method of IoTification, which is the process of IoTifying the existing technology and business models to adopt and leverage IoT. He will drill down to the components in this fra...
Sep. 27, 2016 02:00 AM EDT Reads: 1,727